← Product Code [PBK](/submissions/MI/subpart-d%E2%80%94serological-reagents/PBK) · K222558 # Non-variola Orthopoxvirus Real-time PCR Primer and Probe Set (K222558) _Centers for Disease Control and Prevention · PBK · Aug 30, 2022 · Microbiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/PBK/K222558 ## Device Facts - **Applicant:** Centers for Disease Control and Prevention - **Product Code:** [PBK](/submissions/MI/subpart-d%E2%80%94serological-reagents/PBK.md) - **Decision Date:** Aug 30, 2022 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 866.3315 - **Device Class:** Class 2 - **Review Panel:** Microbiology ## Indications for Use The Non-variola Orthopoxvirus Real-time PCR Primer and Probe Set is intended for the in vitro qualitative presumptive detection of non-variola Orthopoxvirus DNA extracted from human pustular or vesicular rash specimens and viral cell culture lysates submitted to a Centers for Disease Control and Prevention designated laboratory. The assay detects non-variola Orthopoxvirus DNA, including Vaccinia, Cowpox, Monkeypox and Ectromelia viruses at varying concentrations. This assay does not differentiate Vaccinia virus or Monkeypox virus from other Orthopoxviruses detected by this assay and does not detect Variola virus. Refer to the CDC algorithm, Acute, Generalized Vesicular or Pustular Rash Illness Testing Protocol in the United States for recommended testing and evaluation algorithms for patients presenting with acute, generalized pustular or vesicular rash illness. Results of this assay are for the presumptive identification of non-variola Orthopoxvirus DNA. These results must be used in conjunction with other diagnostic assays and clinical observations to diagnose Orthopoxvirus infection. The assay should only be used to test specimens with low/moderate risk of smallpox. If a high risk of smallpox exists, viral culture should not be attempted. Negative results obtained with this device do not preclude Variola virus infection and should not be used as the sole basis for treatment or other patient management decisions. Use is limited to Centers for Disease Control and Prevention designated laboratories. ## Device Story Real-time PCR assay; detects non-variola orthopoxvirus DNA in clinical specimens; utilizes primer and probe sets for amplification and detection; used in clinical laboratory settings by trained personnel; provides qualitative results to aid in diagnosis of orthopoxvirus infection; modification includes additional extraction platforms and updated processing methods for dry and wet swabs. ## Clinical Evidence No clinical data provided in the document; performance characteristics and analytical sensitivity/specificity data are maintained by the CDC. ## Technological Characteristics Real-time PCR assay; utilizes nucleic acid amplification and fluorescent probe detection. Designed for use on standard real-time PCR instrumentation. No changes to materials or software from predicate. ## Regulatory Identification In vitro qualitative detection of non-variola Orthopoxvirus nucleic acids extracted from human specimens or viral culture. ## Predicate Devices - Non-variola Orthopoxvirus Real-time PCR Primer and Probe Set ([K222558](/device/K222558.md) - original clearance) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} FDA U.S. FOOD & DRUG ADMINISTRATION # SPECIAL 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ## I Background Information: A 510(k) Number K222558 B Applicant Centers for Disease Control and Prevention C Proprietary and Established Names Non-variola Orthopoxvirus Real-time PCR Primer and Probe Set D Regulatory Information | Product Code(s) | Classification | Regulation Section | Panel | | --- | --- | --- | --- | | PBK | Class II | 21 CFR 866.3315 - Nucleic Acid Based Reagents For Detection Of Non-Variola Orthopoxviruses | MI - Microbiology | ## II Review Summary: This 510(k) submission contains information/data on modifications made to the submitter's own CLASS II device requiring 510(k). The following items are present and acceptable. 1. The name and 510(k) number of the SUBMITTER'S previously cleared device. 2. Submitter's statement that the INDICATIONS FOR USE/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use). 3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 www.fda.gov {1} device has not changed. This change was for additional extraction platforms for use with the assay and modifications to assay labeling regarding extraction procedures as well as dry and wet swab processing methods. 4. Comparison Information (i.e., similarities and differences) to the submitter's legally marketed predicate device including, labeling, intended use, and physical characteristics. 5. A Design Control Activities Summary which includes: a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis. b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied. The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared device. K222558 - Page 2 of 2 --- **Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/PBK/K222558](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/PBK/K222558) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com